Literature DB >> 26938643

Occurrence, Management, and Risk Factors for Adverse Drug Reactions in Multidrug Resistant Tuberculosis Patients.

Nafees Ahmad1, Arshad Javaid2, Syed Azhar Syed Sulaiman1, Afsar Khan Afridi2, Amer Hayat Khan1.   

Abstract

Although Pakistan has a high burden of multidrug-resistant tuberculosis (MDR-TB), little is known about prevalence, management, and risk factors for adverse drug reactions (ADRs) in MDR-TB patients in Pakistan. To evaluate occurrence, management, and risk factors for ADRs in MDR-TB patients, and its impact on treatment outcomes, this observational cohort study was conducted at programmatic management unit for drug resistant TB of Lady Reading Hospital Peshawar, Pakistan. A total of 181 MDR-TB patients enrolled at the study site from January 1, 2012 to February 28, 2013 were included. Patients with drug resistant TB other than MDR-TB, transferred out patients and those who were still on treatment at the end of study duration (January 31, 2015) were excluded. Patients were followed until treatment outcomes were reported. ADRs were determined by laboratory data and/or clinical criteria. SPSS 16 was used for data analysis. A total of 131 patients (72.4%) experienced at least 1 ADR. Gastrointestinal disturbance was the most commonly observed adverse event (42%), followed by psychiatric disturbance (29.3%), arthralgia (24.3%), and ototoxicity (21%). Potentially life-threatening ADRs, such as nephrotoxicity (2.7%) and hypokalemia (2.8%) were relatively less prevalent. Owing to ADRs, treatment regimen was modified in 20 (11%) patients. On multivariate analysis, the only risk factor for ADRs was baseline body weight ≥ 40 kg (OR = 2.321, P-value = 0.013). ADRs neither led to permanent discontinuation of treatment nor adversely affected treatment outcomes. Adverse effects were prevalent in current cohort, but caused minimal modification of treatment regimen, and did not negatively impact treatment outcomes. Patient with baseline body weight ≥ 40 kg should be closely monitored.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 26938643     DOI: 10.1097/MJT.0000000000000421

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  11 in total

Review 1.  Categorization and association analysis of risk factors for adverse drug events.

Authors:  Lina Zhou; Anamika Paul Rupa
Journal:  Eur J Clin Pharmacol       Date:  2017-12-08       Impact factor: 2.953

2.  A Score to Predict the Risk of Major Adverse Drug Reactions Among Multi-Drug Resistant Tuberculosis Patients in Southern Ethiopia, 2014-2019.

Authors:  Lemlem Bogale; Denekew Tenaw; Tewodros Tsegaye; Mohamed Abdulkadir; Temesgen Yihunie Akalu
Journal:  Infect Drug Resist       Date:  2022-04-21       Impact factor: 4.177

3.  Assessment of Adverse Drug Events, Their Risk Factors, and Management Among Patients Treated for Multidrug-Resistant TB: A Prospective Cohort Study From Pakistan.

Authors:  Farman Ullah Khan; Amjad Khan; Faiz Ullah Khan; Khezar Hayat; Asim Ur Rehman; Jie Chang; Waseem Khalid; Sidra Noor; Asad Khan; Yu Fang
Journal:  Front Pharmacol       Date:  2022-05-17       Impact factor: 5.988

4.  Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study.

Authors:  Workineh Shibeshi; Anandi N Sheth; Addisu Admasu; Alemseged Beyene Berha; Zenebe Negash; Getnet Yimer
Journal:  BMC Pharmacol Toxicol       Date:  2019-05-23       Impact factor: 2.483

5.  Effectiveness and Safety of a Shorter Treatment Regimen in a Setting with a High Burden of Multidrug-Resistant Tuberculosis.

Authors:  Aleksandr Trubnikov; Arax Hovhannesyan; Kristina Akopyan; Ana Ciobanu; Dilbar Sadirova; Lola Kalandarova; Nargiza Parpieva; Jamshid Gadoev
Journal:  Int J Environ Res Public Health       Date:  2021-04-13       Impact factor: 3.390

6.  Active surveillance for adverse events in patients on longer treatment regimens for multidrug-resistant tuberculosis in Viet Nam.

Authors:  Nguyen Bao Ngoc; Hoa Vu Dinh; Nguyen Thi Thuy; Duong Van Quang; Cao Thi Thu Huyen; Nguyen Mai Hoa; Nguyen Hoang Anh; Phan Thuong Dat; Nguyen Binh Hoa; Edine Tiemersma; Nguyen Viet Nhung
Journal:  PLoS One       Date:  2021-09-07       Impact factor: 3.240

7.  Assessment of Factors Associated with Unfavorable Outcomes among Drug-Resistant TB Patients: A 6-Year Retrospective Study from Pakistan.

Authors:  Farman Ullah Khan; Asim Ur Rehman; Faiz Ullah Khan; Khezar Hayat; Amjad Khan; Nafees Ahmad; Jie Chang; Usman Rashid Malik; Yu Fang
Journal:  Int J Environ Res Public Health       Date:  2022-01-29       Impact factor: 3.390

8.  Frequency and Factors Associated With Adverse Events Among Multi-Drug Resistant Tuberculosis Patients in Pakistan: A Retrospective Study.

Authors:  Muhammad Atif; Waqar Ahmed; Muhammad Nouman Iqbal; Nafees Ahmad; Wajiha Ahmad; Iram Malik; Yaser Mohammed Al-Worafi
Journal:  Front Med (Lausanne)       Date:  2022-03-01

9.  Effects of Multidrug Resistant Tuberculosis Treatment on Patients' Health Related Quality of Life: Results from a Follow Up Study.

Authors:  Nafees Ahmad; Arshad Javaid; Syed Azhar Syed Sulaiman; Anila Basit; Afsar Khan Afridi; Ammar Ali Saleh Jaber; Amer Hayat Khan
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

10.  Predictors of unsuccessful interim treatment outcomes of multidrug resistant tuberculosis patients.

Authors:  Muhammad Atif; Arslan Bashir; Nafees Ahmad; Razia Kaneez Fatima; Sehar Saba; Shane Scahill
Journal:  BMC Infect Dis       Date:  2017-09-29       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.